Search

In this century, under the guidance of the basic state policy of conserving resources and the environment, China has made the rich practical experience and great historic achievements in the construction of ecological civilization, but the deployment of China's ecological communication system is relatively late, and the international ecological discourse system is also imperfect. This paper combs the discipline context and development status of ecological communication. Taking the fifteenth meeting of the Conference of the Parties to the UN Convention on Biological Diversity held in Kunming, China, in 2021 as an example, four mainstream Chinese media are selected for analysis, aiming at exploring the inherent law of the ecological communication and excavating the international discourse system of ecological civilization with Chinese characteristics.

Living on Mars requires ability to synthesize living products locally using Martian resources. The synthesis of necessary chemicals from local materials, especially oxygen, which is essential for survival, is a challenging task. Here, we demonstrate a robotic AI-Chemist that automatically synthesizes and intelligently optimizes usable oxygen evolution reaction catalysts from Martian meteorites. The entire process including Martian ore pre-treatment, catalyst synthesis, characterization, and testing, and most importantly, the search of optimal formula, was performed without human intervention. Using a machine learning model derived from both first-principles data and experimental measurements, this methodology automatically and rapidly identified a globally optimal synthetic formula from more than 3 million possible compositions. The synthesized catalyst offers state-of-the-art performance with a current density of 10 mA/cm2 at an overpotential of 445.1 mV for more than 550,000 s, convincingly demonstrating the feasibility of the robotic AI-Chemist in the automatic synthesis of chemicals/materials for Mars exploration.

Hemorrhage is the typical manifestation of APL-related coagulopathy while thrombosis is infrequently reported. In a retrospective analysis with 33 patients with hyperleukocytic APL, we found 6 out of 33 hyperleukocytic APL patients presented with thrombosis rather than hemorrhage. A notable feature in these high-risk APL patients with thrombosis is that there were no significant abnormalities in fibrinogen (FIB), prothrombin time (PT) and activated partial thromboplastin time (APTT). Compared with the normal ranges, both the high-risk APL patients with thrombosis and the high-risk APL patients with hemorrhage had a significant increase in fibrinogen degradation product (FDP) and d-dimer levels. However, the group with hemorrhage had noticeably higher plasma levels of FDP and d-dimer than the group with thrombosis. To find a close relationship between coagulation markers and the onset of thrombotic events in patients with high-risk APL, the potential effects of FDP/FIB and d-dimer/FIB ratios as risk markers were investigated. We demonstrated that FDP/FIB and d-dimer/FIB ratios in the patients with high-risk APL with thrombosis showed higher ratios than the normal range but significantly lower ratios than the patients with high-risk APL-related hemorrhage. Our data demonstrated that the alteration in FDP/FIB and d-dimer/FIB ratios have more significant relevance than the levels of FIB, FDP or d-dimer as potential factors for predicting thrombosis and may help with designing more appropriately risk-adapted treatment protocols or personalized therapy.

Background Decitabine are used in the treatment of myelodysplastic syndrome (MDS), but none trials reported overall survival improvement. Methods High-risk MDS and MDS transformed AML (sAML) patients (IPSS-R > 4.5, age above 60 years) in 6 medical centers of China were treated and compared a new regimen (decitabine with CEG) consisted of low dose decitabine (15 mg/m2, days 1-3), low dose etoposide (30 mg/m2, days 4,6,8,10,12), cytarabine (10 mg/m2 per day, days 4-12) and granulocyte colony-stimulating factor (G-CSF, 5ug/kg, adjusted by patients’ WBC level, 12 hours prior to decitabine administration) with decitabine alone. The endpoints were death and disease progression. Results The baseline characteristics of these 2 groups were equivalent and none patients received prior chemotherapy. The treatment response rate (P= .048) and progression free survival (PFS, P = .030) all demonstrated significant improvement compared with decitabine alone. Decitabine with CEG regimen had attained a CR rate of 45.7%, a median OS of 36 (19-53) months and a median PFS of 34 (16.7-51.3) months in high-risk MDS patients, a CR rate of 40% in sAML. While decitabine alone only attained a median OS of 26 (24.5-27.5) months and a CR rate of 18.2% as well as a median progression free survival of 20 (17.6-22.4) months in MDS patients. Treatment response to CR or PR and TP53 mutation were 2 prognostic factor for OS and PFS in decitabine with CEG regimen. Conclusion Decitabine with CEG regimen showed some promising advantage in elderly, high-risk MDS.

We propose an efficient protocol to fully reconstruct a set of high-fidelity quantum gates. Usually, the efficiency of reconstructing high-fidelity quantum gates is limited by the sampling noise. Our protocol is based on a perturbative approach and has two stages. In the first stage, the initial part of noisy quantum gates is reconstructed by measuring traces of maps, and the trace can be measured by amplifying the noise in a way similar to randomised benchmarking and quantum spectral tomography. In the second stage, by amplifying the non-unital part using the unital part, we can efficiently reconstruct the non-unital part. We show that the number of measurements needed in our protocol scales logarithmically with the error rate of gates.

There is still a lack of effective treatments for elderly AML/MDS patients, especially those with TP53 mutation. We conducted a prospective, multicenter clinical trial to evaluate decitabine and etoposide based regimen in elderly AML/MDS patients and found the median OS of TP53 mutation AML/MDS was improved to 31 months. Moreover, the administration of decitabine and etoposide greatly reduced TP53 mutant AML tumor burden in NSG mice model. Decitabine and etoposide induced significant apoptosis and differentiation of TP53 mutant myeloid tumor cells in vitro. RNA sequencing data and CRISPR-Cas9 gene editing indicated that drug-induced apoptosis and differentiation, were predominantly dependent on Notch1 signaling pathway. We also found that normal p53 function could inhibit Notch1 activation, whereas decitabine and etoposide could activate Notch1 in dysfunctional TP53 mutant AML/MDS. These findings indicate that treatment of elderly AML/MDS patients may need to be developed into a more precise, personalized chemotherapy in the future.

We have demonstrated that 12-0-tetradecanoylphorbol-13-acetate (TPA) combined with vitamin D 3 (VD 3 ) and cytosine arabinoside (Ara C) is effective and feasible for chronic myelogenous leukemia (CML) in blastic phase (BP). In the current study, the efficacy of TPA combined with inhibitor imatinib mesylate (imatinib) was investigated in patients with CML in BP that was resistant to standard-dose imatinib (400 mg/day). The results suggested that TPA combined with imatinib (400 mg/day) might overcome disease-poor response to conventional doses. So this approach deserves further evaluation as frontline therapy for newly diagnosed CML.

We report on the successful fabrication of highly branched CuS nanocrystals by laser-induced photochemical reaction. Surprisingly, the single-crystalline nature with preferential alignment of the (107) orientation can be well improved during the moderate growth process. The branch length drastically increases from about 5 nm to 6 μm with an increase of photochemical reaction time (0–40 min). The absorption spectra of as-prepared CuS nanodendrites show that localized surface plasmon resonance (LSPR) peaks can be modulated from about 1037 nm to 1700 nm with an increase of branch length. Our results have a promising potential for photodynamic therapy and biological imaging application.